ATM and breast cancer: Women who meet genetic testing criteria due to a personal or family history of breast cancer and are heterozygous carriers of a pathogenic variant in ATM have been estimated to be at a two–fourfold increase in breast cancer risk compared to non-carriers [1, 2].